Noble Financial Capital Markets Initiates Coverage on Cynapsus Therapeutics (TSXV:CTH) (OTCBB:CYNAF) with a Buy Recommendation - Video Summary of Report on InvestmentPitch.com
(Thomson Reuters ONE) -
Vancouver, British Columbia, July 10, 2013 - Noble Financial Capital Markets
initiates coverage on Cynapsus Therapeutics (TSXV:CTH) (OTCBB:CYNAF). Research
analyst Nathan Cali gives the company a buy rating and a 12-month target price
of $1.75, which would give investors a projected return of 386% from the $0.36
price at the time the report was issued.
InvestmentPitch.com has produced a "video news alert" about Cynapsus based on
this report. If this link is not enabled, please visit www.InvestmentPitch.com
and enter "Cynapsus" in the search box.
Cynapsus is a specialty pharmaceutical company currently advancing a non-
injection delivery of an already approved drug, apomorphine, for the treatment
of Parkinson's disease. More than 1 million people in the U.S. and an estimated
5 million people globally suffer from Parkinson's disease, a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging population. In the U.S. alone, the
therapeutic market to treat the symptoms and side effects of Parkinson's disease
was $3.6 billion, according to numbers from Symphony Health Solution.
Cynapsus' lead drug candidate, APL-130277, is a reformulation of the approved
Apokyn, which is a chronic use, daily therapeutic for mid to advanced stage
Parkinson's patients experiencing "off" episodes.
It is estimated that between 25% and 50% of patients experience "off" episodes
in which they have impaired movement or speaking capabilities.
Currently, Noble Financial believes the global rescue therapy market is
substantially under penetrated due to the associated side effects of Apokyn,
which often causes significant injection site pain and irritation, in addition
to being difficult to deliver.
Combined Apokyn sales in Europe and U.S. were $60 million in 2012. However, in
Noble Financial's view, upon approval APL-130277's oral administration delivery
will expand the market due to a significantly reduced side effect profile, and a
substantially increased convenience from oral administration.
Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal
studies in advance of a New Drug Application expected to be submitted in 2015.
The company anticipates a trade sale or out-licensing to an appropriate global
pharmaceutical partner before such an application is submitted.
The company is trading at $0.38, well below the target price of $1.75, and with
38.9 million shares outstanding is capitalized at $14.8 million.
For more information, please visit the company's website www.cynapsus.ca, or to
obtain a copy of this extensive research report contact Anthony Giovinazzo at
416-703-2449 ext 225 or email ajg(at)cynapsus.ca.
For more information about Noble Financial Capital Markets or to obtain
additional research, contact them at www.noblefcm.com.
About InvestmentPitch
InvestmentPitch.com, a multimedia company that provides a combined solution for
creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing three minute videos based on news releases and research reports.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan(at)investmentpitch.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via Thomson Reuters ONE
[HUG#1715596]
Unternehmensinformation / Kurzprofil:
Datum: 10.07.2013 - 16:42 Uhr
Sprache: Deutsch
News-ID 277267
Anzahl Zeichen: 4208
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Noble Financial Capital Markets Initiates Coverage on Cynapsus Therapeutics (TSXV:CTH) (OTCBB:CYNAF) with a Buy Recommendation - Video Summary of Report on InvestmentPitch.com"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
